SYNDAX PHARMACEUTICALS INC (SNDX)
US87164F1057 - Common Stock
Overall SNDX gets a fundamental rating of 2 out of 10. We evaluated SNDX against 565 industry peers in the Biotechnology industry. SNDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNDX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SNDX has reported negative net income.
In the past year SNDX has reported a negative cash flow from operations.
SNDX had negative earnings in 4 of the past 5 years.
SNDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SNDX's Return On Assets of -69.76% is on the low side compared to the rest of the industry. SNDX is outperformed by 66.67% of its industry peers.
The Return On Equity of SNDX (-81.07%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.76% | ||
| ROE | -81.07% | ||
| ROIC | N/A |
ROA(3y)-19.55%
ROA(5y)-34.5%
ROE(3y)-21.21%
ROE(5y)-54.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNDX has more shares outstanding than it did 1 year ago.
SNDX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNDX has a worse debt to assets ratio.
2.2 Solvency
SNDX has an Altman-Z score of 8.83. This indicates that SNDX is financially healthy and has little risk of bankruptcy at the moment.
SNDX's Altman-Z score of 8.83 is amongst the best of the industry. SNDX outperforms 81.82% of its industry peers.
SNDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
SNDX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.83 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SNDX has a Current Ratio of 6.99. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SNDX (6.99) is better than 67.38% of its industry peers.
SNDX has a Quick Ratio of 6.99. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
SNDX has a Quick ratio of 6.99. This is in the better half of the industry: SNDX outperforms 67.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.99 | ||
| Quick Ratio | 6.99 |
3. Growth
3.1 Past
The earnings per share for SNDX have decreased strongly by -40.70% in the last year.
EPS 1Y (TTM)-40.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SNDX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.84% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.3%
EPS Next 2Y-11.85%
EPS Next 3Y4.97%
EPS Next 5Y13.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
Also next year SNDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.85%
EPS Next 3Y4.97%
5. Dividend
5.1 Amount
SNDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYNDAX PHARMACEUTICALS INC
NASDAQ:SNDX (11/13/2024, 5:20:02 PM)
After market: 16.57 -0.06 (-0.36%)16.63
+0.42 (+2.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.76% | ||
| ROE | -81.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.99 | ||
| Quick Ratio | 6.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-40.7%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-27.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y